Company Overview and News

0
Group Ten Metals Completes Earn-Ins at Black Lake-Drayton Project in Ontario and Expands Land Position

2018-07-18 globenewswire
VANCOUVER, British Columbia, July 18, 2018 (GLOBE NEWSWIRE) -- Group Ten Metals Inc. (TSX-V:PGE) (US OTC:PGEZF) (FSE:5D32) (the “Company” or “Group Ten”) is pleased to provide an update on the Company’s Black Lake-Drayton gold project, located in the Rainy River district of Northwest Ontario, Canada, including the completion of all outstanding earn-in requirements on two of the claim blocks. The Ontario asset complements Group Ten’s core Stillwater West project with a large and highly prospective land position which is strategically located beside advanced-stage projects in a world-class high-grade gold district.
DCGCF PGE NGD PGEZF TSRMF NGDAF NCPCF TML FFMGF NGD

0
Sandy Lake Gold Inc. wins Arbitration case against Treasury Metals Inc.

2018-07-09 globenewswire
TORONTO, July 09, 2018 (GLOBE NEWSWIRE) -- Sandy Lake Gold Inc. (the”Company” or “SLG”) (TSX-V:SLAU) is pleased to announce a partial award in the Arbitration Proceedings with Treasury Metals Inc. (TSX:TML) formerly Goldeye Explorations Limited (“Goldeye”) (see Treasury Metals press release dated July 11, 2016 available at SEDAR.com).
TSRMF GGY GEYEF TML

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to TSX:TML / Treasury Metals Inc. on message board site Silicon Investor.

Test Your HTML Here Before You Post It! HTML Test
HTML TEST FORUM!! Ciscou0027s Profiles, HTML, Smileys, u0026 Acronyms Reference Thread
Timeline Inc (TMLN) ATML: Atmel Corporation
Yet Another HTML Proving Ground -- Moonshot! testing html limits, any tips?
Atml is a strong buy. ATMLu0027s future